StockData
PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Polaryx Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.92+0.04 (+2.13%)

Close on Oct 19, 2026

Market cap
$92.69M
P/E (TTM)
–
Dividend yield
–

SEC filings

9 of Polaryx Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 10, 2026Sep 14, 2026SEC EDGAR
Current report8-KSep 1, 2026Sep 1, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Proxy statementDEF 14ASep 10, 2026Jul 28, 2026SEC EDGAR
Current report8-KJul 19, 2026Jul 21, 2026SEC EDGAR
Current report8-KJul 16, 2026Jul 17, 2026SEC EDGAR
Current report8-KMay 27, 2026May 28, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 15, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 24, 2026SEC EDGAR